Free Trial
NYSE:BLCO

Bausch + Lomb (BLCO) Stock Price, News & Analysis

Bausch + Lomb logo
$18.00 +0.05 (+0.28%)
(As of 12/20/2024 05:31 PM ET)

About Bausch + Lomb Stock (NYSE:BLCO)

Key Stats

Today's Range
$17.85
$18.20
50-Day Range
$17.95
$20.93
52-Week Range
$13.16
$21.69
Volume
401,500 shs
Average Volume
558,707 shs
Market Capitalization
$6.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.58
Consensus Rating
Hold

Company Overview

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Bausch + Lomb Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
63rd Percentile Overall Score

BLCO MarketRank™: 

Bausch + Lomb scored higher than 63% of companies evaluated by MarketBeat, and ranked 397th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bausch + Lomb has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 5 buy ratings, 7 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Bausch + Lomb has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Bausch + Lomb's stock forecast and price target.
  • Earnings Growth

    Earnings for Bausch + Lomb are expected to grow by 38.33% in the coming year, from $0.60 to $0.83 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bausch + Lomb is -17.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bausch + Lomb is -17.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Bausch + Lomb has a PEG Ratio of 1.74. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Bausch + Lomb has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.13% of the float of Bausch + Lomb has been sold short.
  • Short Interest Ratio / Days to Cover

    Bausch + Lomb has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bausch + Lomb has recently increased by 11.65%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Bausch + Lomb does not currently pay a dividend.

  • Dividend Growth

    Bausch + Lomb does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.13% of the float of Bausch + Lomb has been sold short.
  • Short Interest Ratio / Days to Cover

    Bausch + Lomb has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bausch + Lomb has recently increased by 11.65%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Bausch + Lomb has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Bausch + Lomb this week, compared to 5 articles on an average week.
  • Search Interest

    6 people have searched for BLCO on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Bausch + Lomb to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bausch + Lomb insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.15% of the stock of Bausch + Lomb is held by insiders.

  • Percentage Held by Institutions

    Only 11.07% of the stock of Bausch + Lomb is held by institutions.

  • Read more about Bausch + Lomb's insider trading history.
Receive BLCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter.

BLCO Stock News Headlines

Bausch + Lomb Co. (NYSE:BLCO) Sees Large Growth in Short Interest
WARNING: “Buffett Indicator” flashing for first time in 50 years
Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.
Bausch + Lomb (NYSE:BLCO) Stock Rating Lowered by Citigroup
HC Wainwright Reiterates Buy Rating for Bausch + Lomb (NYSE:BLCO)
Bausch + Lomb responds to rumors of potential sale
Bausch + Lomb Responds to Rumors of a Potential Sale
See More Headlines

BLCO Stock Analysis - Frequently Asked Questions

Bausch + Lomb's stock was trading at $17.06 at the start of the year. Since then, BLCO stock has increased by 5.5% and is now trading at $18.00.
View the best growth stocks for 2024 here
.

Bausch + Lomb Co. (NYSE:BLCO) announced its quarterly earnings data on Wednesday, October, 30th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.01. Bausch + Lomb's revenue for the quarter was up 18.8% on a year-over-year basis.

Bausch + Lomb (BLCO) raised $788 million in an initial public offering (IPO) on Friday, May 6th 2022. The company issued 35,000,000 shares at $21.00-$24.00 per share.

Top institutional investors of Bausch + Lomb include Maple Rock Capital Partners Inc. (1.03%), Goldentree Asset Management LP (0.95%), River Road Asset Management LLC (0.57%) and Whitebox Advisors LLC (0.35%).
View institutional ownership trends
.

Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bausch + Lomb investors own include PayPal (PYPL), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Walt Disney (DIS), Intel (INTC) and Devon Energy (DVN).

Company Calendar

Last Earnings
10/30/2024
Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Ophthalmic goods
Sub-Industry
Medical Equipment
Fax
N/A
Employees
13,300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.58
High Stock Price Target
$26.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+14.4%
Consensus Rating
Hold
Rating Score (0-4)
2.31
Research Coverage
13 Analysts

Profitability

Net Income
$-260,000,000.00
Pretax Margin
-6.00%

Debt

Sales & Book Value

Annual Sales
$4.68 billion
Cash Flow
$1.89 per share
Book Value
$19.72 per share

Miscellaneous

Free Float
351,646,000
Market Cap
$6.34 billion
Optionable
Optionable
Beta
0.43
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NYSE:BLCO) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners